Press releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Nov 13, 2014New CPT Category I Code Facilitates Processing for U.S. Hospitals and Physicians
Boston Scientific Corporation (NYSE: BSX) announced that its subcutaneous implantable defibrillator (S-ICD System™) will have designated Current Procedural Terminology (CPT®) Category I codes...
-
Nov 5, 2014
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2014 Stifel Healthcare Conference on Tuesday, November 18, 2014 in New York City. Dan Brennan, executive vice president...
-
Nov 4, 2014Event will be held in Chicago, Site of the 2014 American Heart Association Scientific Sessions
Boston Scientific Corporation (NYSE: BSX) today announced that it will be holding an analyst event on November 19, 2014 to provide an update on company interventional cardiology initiatives and...
-
Nov 3, 2014Data Will Focus on Long-Term Back Pain Relief Using the Boston Scientific Precision Spectra™ Spinal Cord Stimulator (SCS) System and Highlight Research on Stimulation Waveforms
Boston Scientific Corporation (NYSE: BSX) is reinforcing the company's commitment to developing innovative and effective therapies in neuromodulation. The company will present data on key clinical...
-
Oct 30, 2014
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2014 Credit Suisse Annual Healthcare Conference on Tuesday, November 11, 2014 in Phoenix, AZ. Dan Brennan, executive...
-
Oct 22, 2014
Boston Scientific Corporation (NYSE: BSX) generated sales of $1.846 billion during the third quarter ended September 30, 2014, compared to the company's guidance range for the quarter of $1.790 to...
-
Oct 21, 2014World's First 32-contact SCS Surgical Leads Designed to Provide More Focused Pain Relief for Patients with Chronic Pain
Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) and CE Mark approval for the CoverEdge™ 32 and CoverEdge™ X 32 Surgical Leads, the world's first...
-
Oct 20, 2014First Patient Enrolled in PLATINUM Diversity Trial Evaluating Performance in Women, Black Americans, Latinos/Hispanics, Native Americans and Alaska Natives with Coronary Artery Disease
As part of its commitment to innovation and improving patient outcomes, Boston Scientific Corporation (NYSE: BSX) has initiated the PLATINUM Diversity trial to evaluate the clinical performance of...
-
Oct 16, 2014The innovative devices allow pacemaker patients access to full body MRI scans in 1.5 Tesla and 3.0 Tesla systems
Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval for the ACCOLADETM pacemaker family. When implanted with the company's INGEVITYTM leads, ACCOLADE pacemakers are the first...
-
Oct 8, 2014Comprehensive Clinical Data from Randomized Trials Reviewed
After reviewing updated data and analysis for the Boston Scientific Corporation (NYSE: BSX) WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device, the U.S. Food and Drug Administration (FDA)...